2025-01-012025-12-312025-12-31true11123152Awen Life Sciences Ltd2026-02-27falseiso4217:GBPxbrli:pure111231522024-12-31111231522025-12-31111231522025-01-012025-12-31111231522023-12-31111231522024-12-31111231522024-01-012024-12-3111123152bus:SmallEntities2025-01-012025-12-3111123152bus:AuditExempt-NoAccountantsReport2025-01-012025-12-3111123152bus:FullAccounts2025-01-012025-12-3111123152bus:PrivateLimitedCompanyLtd2025-01-012025-12-3111123152core:WithinOneYear2025-12-3111123152core:AfterOneYear2025-12-3111123152core:WithinOneYear2024-12-3111123152core:AfterOneYear2024-12-3111123152core:ShareCapital2025-12-3111123152core:SharePremium2025-12-3111123152core:RevaluationReserve2025-12-3111123152core:OtherReservesSubtotal2025-12-3111123152core:RetainedEarningsAccumulatedLosses2025-12-3111123152core:ShareCapital2024-12-3111123152core:SharePremium2024-12-3111123152core:RevaluationReserve2024-12-3111123152core:OtherReservesSubtotal2024-12-3111123152core:RetainedEarningsAccumulatedLosses2024-12-3111123152core:LandBuildings2025-12-3111123152core:PlantMachinery2025-12-3111123152core:Vehicles2025-12-3111123152core:FurnitureFittings2025-12-3111123152core:OfficeEquipment2025-12-3111123152core:NetGoodwill2025-12-3111123152core:IntangibleAssetsOtherThanGoodwill2025-12-3111123152core:ListedExchangeTraded2025-12-3111123152core:UnlistedNon-exchangeTraded2025-12-3111123152core:LandBuildings2024-12-3111123152core:PlantMachinery2024-12-3111123152core:Vehicles2024-12-3111123152core:FurnitureFittings2024-12-3111123152core:OfficeEquipment2024-12-3111123152core:NetGoodwill2024-12-3111123152core:IntangibleAssetsOtherThanGoodwill2024-12-3111123152core:ListedExchangeTraded2024-12-3111123152core:UnlistedNon-exchangeTraded2024-12-3111123152core:LandBuildings2025-01-012025-12-3111123152core:PlantMachinery2025-01-012025-12-3111123152core:Vehicles2025-01-012025-12-3111123152core:FurnitureFittings2025-01-012025-12-3111123152core:OfficeEquipment2025-01-012025-12-3111123152core:NetGoodwill2025-01-012025-12-3111123152core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3111123152core:ListedExchangeTraded2025-01-012025-12-3111123152core:UnlistedNon-exchangeTraded2025-01-012025-12-3111123152core:MoreThanFiveYears2025-01-012025-12-3111123152core:Non-currentFinancialInstruments2025-12-3111123152core:Non-currentFinancialInstruments2024-12-3111123152dpl:CostSales2025-01-012025-12-3111123152dpl:DistributionCosts2025-01-012025-12-3111123152core:LandBuildings2025-01-012025-12-3111123152core:PlantMachinery2025-01-012025-12-3111123152core:Vehicles2025-01-012025-12-3111123152core:FurnitureFittings2025-01-012025-12-3111123152core:OfficeEquipment2025-01-012025-12-3111123152dpl:AdministrativeExpenses2025-01-012025-12-3111123152core:NetGoodwill2025-01-012025-12-3111123152core:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3111123152dpl:GroupUndertakings2025-01-012025-12-3111123152dpl:ParticipatingInterests2025-01-012025-12-3111123152dpl:GroupUndertakingscore:ListedExchangeTraded2025-01-012025-12-3111123152core:ListedExchangeTraded2025-01-012025-12-3111123152dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-01-012025-12-3111123152core:UnlistedNon-exchangeTraded2025-01-012025-12-3111123152dpl:CostSales2024-01-012024-12-3111123152dpl:DistributionCosts2024-01-012024-12-3111123152core:LandBuildings2024-01-012024-12-3111123152core:PlantMachinery2024-01-012024-12-3111123152core:Vehicles2024-01-012024-12-3111123152core:FurnitureFittings2024-01-012024-12-3111123152core:OfficeEquipment2024-01-012024-12-3111123152dpl:AdministrativeExpenses2024-01-012024-12-3111123152core:NetGoodwill2024-01-012024-12-3111123152core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3111123152dpl:GroupUndertakings2024-01-012024-12-3111123152dpl:ParticipatingInterests2024-01-012024-12-3111123152dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-012024-12-3111123152core:ListedExchangeTraded2024-01-012024-12-3111123152dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-012024-12-3111123152core:UnlistedNon-exchangeTraded2024-01-012024-12-3111123152core:NetGoodwill2025-12-3111123152core:IntangibleAssetsOtherThanGoodwill2025-12-3111123152core:LandBuildings2025-12-3111123152core:PlantMachinery2025-12-3111123152core:Vehicles2025-12-3111123152core:FurnitureFittings2025-12-3111123152core:OfficeEquipment2025-12-3111123152core:AfterOneYear2025-12-3111123152core:WithinOneYear2025-12-3111123152core:ListedExchangeTraded2025-12-3111123152core:UnlistedNon-exchangeTraded2025-12-3111123152core:ShareCapital2025-12-3111123152core:SharePremium2025-12-3111123152core:RevaluationReserve2025-12-3111123152core:OtherReservesSubtotal2025-12-3111123152core:RetainedEarningsAccumulatedLosses2025-12-3111123152core:NetGoodwill2024-12-3111123152core:IntangibleAssetsOtherThanGoodwill2024-12-3111123152core:LandBuildings2024-12-3111123152core:PlantMachinery2024-12-3111123152core:Vehicles2024-12-3111123152core:FurnitureFittings2024-12-3111123152core:OfficeEquipment2024-12-3111123152core:AfterOneYear2024-12-3111123152core:WithinOneYear2024-12-3111123152core:ListedExchangeTraded2024-12-3111123152core:UnlistedNon-exchangeTraded2024-12-3111123152core:ShareCapital2024-12-3111123152core:SharePremium2024-12-3111123152core:RevaluationReserve2024-12-3111123152core:OtherReservesSubtotal2024-12-3111123152core:RetainedEarningsAccumulatedLosses2024-12-3111123152core:NetGoodwill2023-12-3111123152core:IntangibleAssetsOtherThanGoodwill2023-12-3111123152core:LandBuildings2023-12-3111123152core:PlantMachinery2023-12-3111123152core:Vehicles2023-12-3111123152core:FurnitureFittings2023-12-3111123152core:OfficeEquipment2023-12-3111123152core:AfterOneYear2023-12-3111123152core:WithinOneYear2023-12-3111123152core:ListedExchangeTraded2023-12-3111123152core:UnlistedNon-exchangeTraded2023-12-3111123152core:ShareCapital2023-12-3111123152core:SharePremium2023-12-3111123152core:RevaluationReserve2023-12-3111123152core:OtherReservesSubtotal2023-12-3111123152core:RetainedEarningsAccumulatedLosses2023-12-3111123152core:AfterOneYear2025-01-012025-12-3111123152core:WithinOneYear2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:CostValuation2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-012025-12-3111123152core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3111123152core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-3111123152core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-3111123152core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-3111123152core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-3111123152core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-3111123152core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-12-3111123152core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-3111123152core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-3111123152core:Non-currentFinancialInstrumentscore:CostValuation2024-12-3111123152core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-12-3111123152core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-12-3111123152core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-12-3111123152core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-12-3111123152core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-12-3111123152core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-12-3111123152core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-12-3111123152core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-12-3111123152bus:EntityNoLongerTradingButTradedInPast2025-01-012025-12-3111123152bus:Director12025-01-012025-12-31

Awen Life Sciences Ltd

Registered Number
11123152
(England and Wales)

Unaudited Dormant Financial Statements for the Year ended
31 December 2025

Awen Life Sciences Ltd
Company Information
for the year from 1 January 2025 to 31 December 2025

Director

HUGHES CRAMERI, Melya, Dr

Registered Address

26 Berkeley Square
Bristol
BS8 1HP

Place of Business

Casa 15 Pedecosta

San Carlo

Switzerland

7741


Registered Number

11123152 (England and Wales)
Awen Life Sciences Ltd
Statement of Financial Position
31 December 2025

Notes

2025

2024

£

£

£

£

Current assets
Cash at bank and on hand1,5822,972
1,5822,972
Creditors amounts falling due within one year4(16,417)(16,193)
Net current assets (liabilities)(14,835)(13,221)
Total assets less current liabilities(14,835)(13,221)
Net assets(14,835)(13,221)
Capital and reserves
Called up share capital100100
Profit and loss account(14,935)(13,321)
Shareholders' funds(14,835)(13,221)
The financial statements were approved and authorised for issue by the Director on 27 February 2026, and are signed on its behalf by:
HUGHES CRAMERI, Melya, Dr
Director
Registered Company No. 11123152
Awen Life Sciences Ltd
Notes to the Financial Statements
for the year ended 31 December 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:
2.Average number of employees

20252024
Average number of employees during the year01
3.Tangible fixed assets
4.Creditors: amounts due within one year

2025

2024

££
Other creditors15,42615,425
Accrued liabilities and deferred income991768
Total16,41716,193
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.